COMUNICADO: El Journal of the American Medical Association publica el estudio RIO-North America (y 3)

Actualizado 15/02/2006 14:31:59 CET


Contactos de medios: Nazira Amra, +33-1-53-77-47-88,

Julissa Viana, +1-908-243-1232,


(1) Sharma A. M. Adipose tissue: a mediator of cardiovascular risk. Int J

Obes Relat Metab Disord. 2002; 26 Suppl 4: S5-S7

(2) Van Gaal L.F., Rissanen A.M, Sheen A.J., Ziegler O., Rossner S., for

the RIO-Europe study group. Effects of the cannabinoid-1 receptor

blocker rimonabant on weight reduction and cardiovascular risk

factors in overweight patients: 1-year experience from the RIO-Europe

study. Lancet 2005; 365:1389-97.

(3) Despres J-P., Golay A., Sjostrom L., for the RIO-Europe study group.

Effects of rimonabant on metabolic risk factors in overweight

patients with dyslipidemia. New Engl J Med 2005; 353:2121-34.


Página web:

Contacto: Nazira Amra, +33-1-53-77-47-88,, Julissa Viana, +1-908-243-1232,, ambos de sanofi-aventis; Company News On-Call: